We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Contact Lens-Associated Infectious Keratitis: Update on Diagnosis and Therapy

*Jimena Alamillo-Velazquez, Raul E. Ruiz-Lozano,
Julio C. Hernandez-Camarena
and Alejandro Rodriguez-Garcia*

Abstract

The focus of this chapter is to review the most recent advances in the diagnosis and treatment of contact-lens-related infectious keratitis, the most sight-threatening complication of contact lens wear. In the last decades, contact lenses technology has confronted several challenges, including the need for safer and more comfortable polymer materials. The development of high coefficient oxygen permeability (Dkt) and low-water content disposable contact lens translated into a significant improvement in ocular discomfort related to dry eye and allergic reactions, decreasing biofilm build-up on the external surface of the lens. Additionally, the emergence and boom-effect of corneal refractive surgery have also driven the development of better contact lens manufacturing. Despite these substantial technological advances, contact lens users continue to be at risk for developing corneal infections. We describe recent epidemiologic data, and advances in understanding the complex pathogenesis of the disease, including the clinical characteristics of the infectious process produced by bacteria, fungi, and protozoans. Finally, the recent development of diagnostic techniques and therapeutic regimens are discussed.

Keywords: contact lens, infectious keratitis, bacteria, fungi, *Acanthamoeba*

1. Introduction

Contact lenses are a useful tool for correcting refractive errors; over 125 million people wear them worldwide [1]. The widespread use of contact lenses is associated with a variable range of complications up to 39–60.99% of contact lens wearers. Complications range from mild superficial punctate keratitis to vision-threatening conditions such as contact-lens-related infectious keratitis. Infectious keratitis is a potentially blinding condition, and it rarely occurs in healthy eyes; it comprises bacterial, fungal, and *Acanthamoeba* keratitis. Contact lens wear is, in fact, the predisposing factor in up to 50.3% for infectious keratitis [2–4]. Contact lens wear is the most critical risk factor for microbial keratitis in developed countries and the second one in developing countries after trauma [5–8]. Despite different contact lens materials and wearing modalities, infectious keratitis continues to be a sight-threatening condition in contact lens wearers, with a rate of visual loss of up to

28.6% [3, 9]. The annual incidence rate for contact lens-related microbial keratitis is 2/10 000 for rigid contact lens users, 2.2–4.1/10 000 for those who use daily-wear soft contact lens, 13.3–20.9/10 000 for extended wear soft contact lens users, and 52/10 000 for patients who wear therapeutic contact lenses [10].

2. Definition

A classical definition of contact lens-associated infectious keratitis (CLAIK) includes a corneal epithelial defect or ulcer, accompanied by a stromal infiltrate, requiring corneal scraping and culturing [11]. However, corneal cultures are not readily available for all practitioners, suggesting a purely clinical definition [11]. Stapleton et al. proposed the following definition: a corneal infiltrate with an overlying epithelial defect and one or more of the following: lesions within the 4 mm of the central cornea, anterior chamber reaction, and pain [12].

3. Epidemiology

The annual incidence of CLAIK per 10 000 wearers ranges from 0.4–4.0 for rigid gas permeable (RGP) contact lenses, 2.2–4.5 for daily use of soft contact lenses, and 9.3–20.9 for overnight soft contact lenses wear [11]. Hence, daily wear of RGP contact lenses continues to have the lowest infectious keratitis rates [12]; however, the incidence of associated microbial keratitis remains unchanged despite the development of new contact lens materials [13].

Orthokeratology (ortho-K) for myopia prevention and cosmetic and decorative lenses have recently gained popularity among young wearers. On the one hand, ortho-K patients are closely monitored during treatment by their practitioners; conversely, cosmetic contact lens wear (color or party) lacks care education and professional supervision. There are reports of microbial keratitis in both wear modalities [14, 15]. In the case of cosmetic lens wear not dispensed by eye care professionals, a report shows an increased risk of infectious keratitis by a factor of 12.3 (OR 95%-CI = 4.8–31.5). Furthermore, lack of lens care education in the same study increased the risk of infectious keratitis by 26.5 times (OR 95%-CI = 10.0–70.2) [16].

4. Etiology

CLAIK is mainly attributed to bacterial pathogens with up to 90% of the cases (**Table 1**). Moreover, although fungal and protozoal infections are infrequent, they are more severe [24]. The most common bacterial agent involved in CLAIK is *Pseudomonas aeruginosa*, according to several reports (**Figure 1A** and **B**). Gram-negative bacteria are more frequently isolated in tropical climates. Gram-positive bacteria are more commonly identified in regions with temperate climates like Australia and France [2, 3, 11]. Such bacteria include coagulase-negative *Staphylococcus* (including *Staphylococcus epidermidis*), *Staphylococcus aureus*, and *Streptococcus pneumoniae*. *S. aureus* is associated with more severe disease and recurrent infections [25].

On the other hand, keratitis caused by *Acanthamoeba* and fungi has increased in the past few years [26]. In 2006, an outbreak of CLAIK caused by *Fusarium* was first reported in Singapore [27], followed by multiple reports in the United States [28–30]; these outbreaks were directly linked to a particular contact lens solution formulation reported a decreased antifungal activity [31]. In the same year,

Microorganism	Frequency (%)
<i>Pseudomonas aeruginosa</i>	6–55.55% [3, 17–22]
Other coagulase-negative <i>Staphylococcus spp.</i>	8–17.64% [20–22]
<i>Serratia marcescens</i>	2–17.1% [3, 17–22]
<i>Staphylococcus aureus</i>	2–12.5% [3, 19–22]
<i>Acanthamoeba spp.</i>	1.96–12.5% [3, 19, 21]
<i>Fusarium spp.</i>	2–12.5% [19, 21, 22]
<i>Propionibacterium acnes</i>	11.76% [21]
<i>Mycobacterium chelonae</i>	6.4% [23]
<i>Streptococcus spp.</i>	3.92–5.9% [20, 21]
<i>Nocardia spp.</i>	1–1.96% [21, 22]
<i>Klebsiella spp.</i>	0–1% [22]

Table 1.
Prevalence of causal microorganisms of contact lens-associated infectious keratitis.

Figure 1.
A. The left cornea of a patient with a five day-history of red-eye, discharge, and pain after wearing disposable contact lenses overnight. Conjunctival chemosis and ciliary injection are present; a dense stromal infiltrate, 2 mm hypopyon, and a shallow anterior chamber are observed. B. Fluorescein staining shows an extensive overlying epithelial defect. The smear staining revealed a Gram-negative rod, and the culture confirmed the diagnosis of *Pseudomonas aeruginosa*.

outbreaks of *Acanthamoeba* keratitis were also reported and partly associated with another contact lens solution [32].

It is noteworthy to mention the occurrence of CLAIK associated with multiple microorganisms. A retrospective analysis of CLAIK, performed by Karaca et al., demonstrated that 20% (12 cases) were mixed infections. All of them were mixed bacterium-bacterium infections. *P. aeruginosa* was involved in eight cases [33]. Regarding mixed fungi-bacterial infections, Ahn et al. reported a prevalence of 4.4% (33/757). Ocular trauma (45.5%) and diabetes mellitus (18.2%) were the most frequent associated risk factors for mixed bacterial and fungal keratitis, and *Fusarium spp.* and *Staphylococcus spp.* were the most frequent fungi and bacteria isolated, respectively [34].

5. Risk factors

Among the many different risk factors predisposing to CLAIK, overnight wear and poor hygiene are the two most frequent ones, accounting for 43% and 33%

Risk factors	Highest risk	Lowest risk
Modifiable		
Wear schedule	Overnight use	Daily wear only
Days of weekly use	6–7 days	≤ 2 days
Hand washing before cleaning	Not always	Always
Contact lens type	Daily disposable	Rigid lenses [36]
Current smoker	Yes	No
Case hygiene/replace time	Poor	Excellent
Purchase of contact lens	Internet/mail order	Optometrist [12]
Showering with lenses	Yes	No [40]
Water exposure ¹	Yes ²	No [41]
Ocular surface and systemic diseases	Presence	absence [42]
Non-modifiable		
Gender	Male	Female
Age	≤ 49 years	≥ 50 years [36]
Socioeconomic status ³	High [12]	Low [3]
Caucasian race ¹	Yes	No [41]
Previous ocular trauma	Presence	Absence [42]

¹Especially related to *Acanthamoeba keratitis*.
²High risk when exposure to ocean/sea/river/lake water and highest risk when swimming in public or private pool and hot tub.
³Low socioeconomic status is associated with higher risk of *Acanthamoeba keratitis*.

Table 2.
Modifiable and non-modifiable risk factors associated with contact lens-associated infectious keratitis.

of the cases, respectively [35]. Regarding corneal infection in overnight wear, the risk is higher with increased extended wear and inexperienced patients [36, 37]. Interestingly, in severe keratitis, mishandling of the contact lens case (poor hygiene and lack of replacement) accounts for 63% of the population-attributed risk for bacterial and fungal infection. Moreover, swimming with contact lenses on and traveling are also risk factors for infection. The former for *Acanthamoeba keratitis*, and the latter related to routine wearing changes [3, 38].

Other risk factors of infectious keratitis in contact lens wearers include being a male, probably related to poor compliance and reluctance to seek regular care attention [39]. Genetic susceptibility related to small mutations of defensins, interleukins, and other inflammatory mediators seems to play a role in CLAIK (Table 2) [43].

6. Pathogenesis

The primary vector for bacterial transmission in CLAIK is the contact lens through various contaminants, including the eyelids, hands, storage case, cosmetics, and contaminated water or lens solutions [44, 45]. Contact lenses wear alone alters the normal physiology of the cornea. To a greater or lesser extent, the local hypoxia induced by contact lenses causes a decreased epithelial metabolic rate, resulting in epithelial thinning, loss of tight cell junctions, and hemidesmosomes,

which lead to epithelial abrasions predisposing to opportunistic infections. Other corneal hypoxic effects include vascularization and hypoesthesia.

The understanding of CLAIK pathogenesis has changed over time as contact lens materials evolved. Contact lens wear increased in popularity when soft hydrogel contact lenses were introduced, given a higher comfort for the wearer [46]. However, their intrinsic low-oxygen transmissibility was demonstrated to be problematic. It is well-known that lower oxygen transmissibility is related to a higher rate of bacterial binding to the corneal surface; hypoxic conditions in human corneas increase wild-type cystic fibrosis transmembrane conductance regulator (CFTR) expression, which is the cellular receptor for *Pseudomonas aeruginosa*. Hence a lower bacterial load can induce infectious keratitis and inflammatory responses in this type of contact lenses [47]. Previous reports show that decreasing oxygen permeability of contact lenses is associated with increased desquamation of superficial epithelial cells of the cornea [48–50]. These observations led to development and innovation in contact lens materials to address the problem of hypoxia, which led to the advent of highly oxygen-transmissible, soft silicone hydrogel contact lenses. With the introduction of silicone hydrogel soft contact lenses, a decrease in infectious keratitis cases was anticipated; this was hypothesized because of their increased oxygen permeability and decreased bacterial binding [50]. However, no difference in the incidence of infectious keratitis was observed; clinical characteristics, pathogens, and rate of vision loss also remained unchanged despite the new contact lens material [1].

Because solving the hypoxia mechanism did not result in a reduced incidence rate of microbial keratitis, other alternative pathogenic mechanisms are suggested for corneal infection, including inadequate tear exchange. Deficient tear exchange leads to the entrapment of debris and microbes on the posterior surface of contact lenses and hinders the natural antimicrobial functions of the tear film. In fact, there is a reduction in the antimicrobial activity of the tear film on the posterior surface of silicone hydrogel soft contact lenses after 8 hours of wearing them [51]. This mechanism could explain why soft contact lenses are associated with a higher risk of infectious keratitis than rigid gas permeable lenses, given the inadequate tear exchange in the former [52, 53].

Microbes responsible for infectious keratitis may come from the lid margins, the wearers' fingers upon contact lens insertion, or removal, directly from the contact lens or indirectly from the storage case or the lens care solution [54]. Contact lens case contamination has been reported in up to 80% of contact lens wearers, despite adequate compliance with care regimens [55, 56]. The formation of bacterial biofilm on the contact lens surface and storage cases has been previously reported, and it may also play a role in the pathogenesis of microbial keratitis [56]. Bacterial cells within a biofilm show increased resistance to antimicrobial agents [57]. Moreover, multiple biguanide-based contact lens solutions have no effect against biofilms of *Serratia marcescens*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa* formed in silicone hydrogel contact lenses [58]. Also, outbreaks of keratitis caused by *Acanthamoeba* and *Fusarium spp* have been linked to specific contact lens solutions [26, 27, 32].

Animal models have also been used to improve understanding CLAIK. In mouse and guinea pig models, a corneal erosion must occur to produce infectious keratitis; animals with non-scratched corneas only show non-infectious inflammatory responses [59]. This has led to the hypothesis that a corneal defect or erosion is a prerequisite for CLAIK to occur and not microbial contamination alone [60]. Corneal erosions are known complications in contact lens wearers, especially on extended wear schedules [61, 62].

Figure 2.
Flow chart showing the relationship between the risk factors and the main events involved in the pathogenesis and development of contact lens-associated infectious keratitis.

Several risk factors have been associated with microbial keratitis. The most consistent factor is overnight wear, which increases the risk for microbial keratitis by 10 to 15 times compared to daily wear, irrespective of lens type [9, 12, 50, 63–65]. The extended wear risk of infectious keratitis also increases by 9 times with aphakia correction in elderly patients; 12 times greater in patients misusing daily-wear lenses for overnight wear. Other risk factors include contact lens case hygiene, inadequate or lack of handwashing, infrequent case replacement, and smoking; wearing contact lenses while swimming or showering also increases the risk [27, 17, 66–71]. Contact lens wearers who live or travel to tropical locations also have a higher risk for microbial keratitis [18]. According to the lens type, the risk for microbial keratitis is as follows: daily disposable < rigid gas permeable < daily wear of soft contact lens < extended wear of soft contact lens [3, 35, 72].

Furthermore, contact lens wear results in a decrease in basal cell proliferation on the cornea and vertical migration of differentiated cells to the surface of the epithelium, and an abnormal accumulation of older epithelial cells [73, 74].

The pathogenesis of CLAIK is complex and involves intrinsic lens properties, including lens material and oxygen transmissibility and environmental variables such as bacterial contamination; user behavior, such as schedule wear and poor hygiene coupled with the alteration of normal corneal physiology, loss of epithelial adherence mechanisms and corneal erosions, lead to the development of microbial keratitis [12]. In summary, microbial contamination of the lens is followed by microbial adhesion to the corneal epithelium; then microtrauma or erosion to the epithelium occurs, resulting in the microbial invasion of the corneal stroma (**Figure 2**) [75].

7. Diagnosis

Proper diagnosis of CLAIK is based on a complete ocular history of contact lens wear, patient's symptoms, a complete ophthalmological examination, corneal scrape, and culture, including the removed contact lens, the case, and solution [66].

7.1 Symptoms and signs

Symptoms common to microbial keratitis include a rapid onset of ocular pain, red eye, tearing, foreign body sensation, conjunctival mucopurulent discharge, and

Figure 3.
 53 years-old diabetic female using a one-month schedule silicone hydrogel disposable soft contact lenses in an overnight extended wear mode. The patient had been treated with 0.3% ciprofloxacin and prednisolone acetate 1% for one week. One day after stopping medications, a scrape and culture confirmed *Staphylococcus* spp. infection. A. Left cornea showing three round dense stromal infiltrates with moderate stromal edema and Descemet folds. B. Positive fluorescein staining (>80% lesion surface) demarcating extensive corneal ulceration in all lesions. C. Three weeks on intense topical regime of 0.5% moxifloxacin and fortified vancomycin (50 mg/ml), the ulcers resolved.

photophobia with a variable degree of vision loss. These symptoms are accompanied by prominent signs including, eyelid swelling, ciliary injection, conjunctival chemosis, a corneal epithelial defect or ulceration, stromal inflammatory/microbial infiltrate, edema, endothelial keratic precipitates (KPs), and anterior chamber reaction (inflammatory cells, flare, fibrin, plasmoid bodies, hypopyon) [11, 76–78].

There are clinical features that may guide the clinician to a possible etiological agent. Bacterial keratitis is characterized by a round, or oval epithelial defect with an underlying stromal infiltrate and anterior chamber reaction or hypopyon (**Figure 3A–C**) [66].

The classical findings in *Acanthamoeba* keratitis are severe pain that is disproportionate to the clinical signs, ring-shaped corneal infiltrates, and radial perineuritis [69, 75]. Fungal keratitis may present with a grayish, deep infiltrate with feathery borders and satellite lesions or an endothelial plaque and usually has a more insidious course [27, 66, 69]. However, these clinical findings are often misleading; in fact, cornea specialists distinguish correctly bacterial from fungal keratitis only 66% of the time in a photographic survey [79]. Thus, corneal scrapings and cultures remain the gold standard for microbial identification and the only method for determining antibiotic sensitivity [80].

7.2 Smear staining and culture

Corneal scrapings are obtained in the office under the slit lamp. A topical anesthetic agent is instilled, ideally proparacaine hydrochloride 0.5% or a preservative-free anesthetic [81]. The corneal material is obtained with a sterile platinum spatula, blade, forceps, or a calcium alginate swab moistened in thioglycolate broth. The smear stains helpful in identifying the causative organism are Gram stain, Giemsa stain, and Acridine orange are the most frequently used for detecting bacteria. The Gram stain permits identification of gram-positive and -negative coccus and rods, which is essential to choose the initial antibiotic type before the antibiogram and sensitivity profile of the microorganism in question is available. For example, cephalosporins are more appropriate for gram-positive and aminoglycosides for gram-negative bacteria [82].

In case of presumptive fungal infection, special stains like potassium hydroxide (KOH) and calcofluor white (CFW) are more reliable to initiate antifungal therapy than Gram staining is for bacterial infection (**Figure 4A and B**) [82, 83].

Figure 4.
A. Potassium hydroxide (KOH) preparation of a corneal smear from a fungal CLAIK patient, showing septate, branched, hyaline hyphae characteristic of filamentous fungus. B. Sabouraud dextrose agar (SDA) plate showing white, cottony colonies consistent with *Fusarium solani*.

Staining technique	Visualized microorganisms
Gram	Bacteria, fungi and <i>Acanthamoeba</i>
Giemsa	Bacteria, fungi and <i>Acanthamoeba</i>
Potassium hydroxide (KOH)	Fungi
Acridine orange	Bacteria, fungi and <i>Acanthamoeba</i>
Calcofluor white (CFW)	Fungi and <i>Acanthamoeba</i>
Acid fast (modified Ziehl-Neelsen)	Mycobacteria and <i>Nocardia</i> [82, 84]

Table 3.
Most used microorganism identification staining techniques for the diagnostic confirmation of contact lens-associated infectious keratitis.

Mycobacterial or *Nocardia* infection will require the acid-fast or modified Ziehl-Neelsen (1% H₂SO₄, cold) staining (**Table 3**).

According to the American Academy of Ophthalmology Bacterial Keratitis Preferred Practice Pattern, cultures and smears should be obtained in cases of suspected microbial keratitis in the following conditions:

- the presence of a large, central infiltrate and/or accompanied with stromal melting
- chronic or unresponsive infection despite broad-spectrum antibiotic therapy
- atypical clinical findings suggestive of fungal, protozoal, or mycobacterial agents
- multifocal infiltrates or a history of corneal surgery [82].

Corneal scrapings should be directly inoculated into the culture media at room temperature and immediately taken to the laboratory for further processing. If culture media are not readily available, scrapings should be inoculated into transport media, including brain-heart infusion media and amies medium with charcoal. Both transport media may be used for aerobic and facultative anaerobic bacteria and, the latter, also for fungi [82]. Standard culture media include blood agar, chocolate agar, Sabouraud dextrose agar, thioglycolate broth, and mannitol salt agar. If *Acanthamoeba* is the suspected pathogen, a non-nutrient agar with *Escherichia coli* overlay must be used (**Table 4**) [82, 85]. In addition to culturing corneal scrapings, cultures of the contact lens and case can also yield positive results. Corneal scrapings

Standard media	Isolates
Blood agar	Aerobic, anaerobic, and facultative anaerobic bacteria. <i>Pseudomonas aeruginosa</i> , <i>Staphylococcus aureus</i> , <i>Staphylococcus epidermidis</i> , <i>Streptococcus pneumoniae</i> Saprophytic fungi and <i>Nocardia</i> .
Chocolate agar	Aerobic, anaerobic, and facultative anaerobic bacteria. Ideal for isolation <i>Haemophilus influenzae</i> , <i>Neisseria gonorrhoeae</i> , and <i>Moraxella</i> .
Sabouraud dextrose agar	Fungi and <i>Nocardia</i>
Mannitol-salt agar	<i>Staphylococcus spp.</i>
Thioglycolate broth	Aerobic and anaerobic bacteria
Supplemental media	Isolates
CDC anaerobe blood agar	<i>Propionibacterium acnes</i> , <i>Peptostreptococcus spp.</i>
Non-nutrient agar with <i>E. coli</i>	<i>Acanthamoeba spp.</i>
Transport media	Isolates
Brain-heart infusion broth	Filamentous fungi and yeasts. Aerobic and facultative anaerobic bacteria.
Amies medium without charcoal	Aerobic and facultative anaerobic bacteria. Fungi [66, 82, 84, 85]

Table 4.
Respective culture media type used for microorganism isolation in contact lens-associated infectious keratitis.

culture provides positive results in 34–44% cases [67, 86–88], while cultures of contact lenses are positive in 67–92%, and 80–85% for contact lens cases [66]. Studies have found an association between cultures of corneal scrapings and of contact lenses, with a concordance of up to 84% [67, 89]. Therefore, contact lens culture may guide in the identification of the causative organism in cases in which the corneal scraping culture is negative; however, contact lens cultures do not replace corneal cultures as the gold standard for the etiologic diagnosis of microbial keratitis [67].

7.3 Tissue biopsy

A corneal biopsy may be performed if there is an inadequate response to treatment or if cultures are repeatedly negative, particularly for suspicious *Acanthamoeba* keratitis (**Figure 5A–C**). It can be performed at the slit-lamp or in the operating room using topical anesthesia and a small 2 or 3-mm dermatologic trephine punch; the tissue obtained is then bisected and sent for culture and histopathologic analysis. A section of the corneal specimen is homogenized with trypticase soy broth and cultured on conventional blood and chocolate agar, anaerobic media, Sabouraud agar, and thioglycolate broth; in specific cases, the corneal specimen may also be plated on a non-nutrient agar with *E. coli* or Lowenstein Jensen media. The specimen section that is sent for histopathologic analysis may be processed with standard stains for bacteria, fungi, acid-fast-bacilli, and *Acanthamoeba* such as Gram and Giemsa stain, potassium hydroxide, calcofluor white and, Ziehl-Neelsen [90]. Several considerations should be taken into account to maximize the diagnostic yield of a corneal biopsy [90–92]:

- To obtain the tissue specimen, topical antibiotics must be suspended at least 24–48 hours before the procedure [90]. Also, appropriate planning and consultation with the microbiologist and pathologist is recommended (i.e., need for special stains for fastidious organisms, appropriate fixatives if electron microscopy is required) [91].

- The biopsy must be performed under appropriate magnification at either the operating room or under the slit lamp, with free lamellar dissection using a diamond-sharp blade, set at 0.2 to 0.3 mm depth, or a 3 to 5 mm diameter trephine (skin biopsy punches), cutting to approximately 0.2 to 0.3 mm depth to avoid corneal perforation [92]. After trephination, the base of the tissue block must be gently pulled upward and sideways with a Colibri 0.12 mm tooth forceps to cut it off with a sharp knife (i.e., Grieshaber knife, Beaver blade No.66) or a Vannas scissors, completing the lamellar keratectomy [92].
- The tissue biopsy must include a leading edge of the infiltrate or ulcer, including an uninvolved tissue margin [91].
- The tissue sample's processing technique (i.e., electron and light microscopy histopathologic analysis, immunofluorescence, or histochemistry) depends on the clinical features and the amount of tissue available. For small specimens (<3 mm), it is suggested to use only the technique potentially yielding the best result, which must be selected based on a clinical suspicion [91].
- If a large sample is obtained, the specimen is divided under sterile technique with a sharp #11 or a 15° knife. Each portion is placed in the appropriate fixative [92].
- With a cotton-tipped applicator or a moistened cellulose (Weck-cel) sponge, swab the base of the keratectomy and streak the culture material on plates containing transport media [92].

7.4 Molecular biology techniques

The most common approach to diagnose CLAIK is to culture microorganisms from corneal scrapings. However, more than 99% of the biosphere's microbes are

Figure 5. Left cornea from a hardware store worker with keratoconus fitted with RGP contact lenses used to wash his face with stagnant water in an open tank deposit. A. Dense ring infiltrate with multiple stromal satellite nummular lesions and anterior chamber reaction. B. A 3 mm diameter corneal biopsy stained with H&E (mag. 40x), showing multiple *Acanthamoeba* cysts in the corneal stroma. C. Modified Giemsa stain from the same biopsy piece enhancing the presence of multiple *Acanthamoeba* cysts.

not cultivable using standard laboratory culture techniques [93]. Furthermore, identifying slow-growing bacteria (e.g., atypical mycobacteria) or fungi with atypical phenotypes is tedious and time-consuming [94]. The advent of molecular culture-independent high-throughput sequencing approaches has allowed further identification and characterization of microorganisms that cause CLAIK [95].

7.4.1 Polymerase chain reaction (PCR)

PCR is a highly sensitive technique that allows rapid amplification of tiny samples of DNA. In the context of infection, it may be used to detect the presence of pathogenic DNA of specific microorganisms [96]. The 16S and 18S rRNA are the most frequently used marker genes for assessing bacterial and fungal profiles, respectively. They are found in all respective microorganisms and have enough variation for phylogenetic analysis and sequence conservation for accurate alignment [97]. The 16S rRNA gene sequence is 1,550 bp long, and it is composed of nine variable regions (V1-V9) interspaced in more conserved regions. By amplifying the 16S rRNA region with PCR, the background host contamination encountered in routine culturing techniques is reduced significantly [98].

Kim et al. compared the detection rate of PCR compared with traditional cultures in patients with infectious corneal ulcers [99]. Of 108 samples taken from ulcers, 52% were culture-positive and 89% PCR-positive for fungal primers (18S rRNA), bacterial primers (16S rRNA), or both. Of note, other nonpathogenic organisms (i.e., *Ralstonia*, *Oerksovia*, and *Leclercia* species) were also identified in 60% and 52% of the PCR samples and control swabs, respectively. Airborne contamination and false-positive results for pan-fungal and pan-bacterial PCR constitute a significant limitation of the technique [100]. Moreover, when analyzing culture-positive samples, 24% and 6.5% were PCR-negative for bacteria and fungi, respectively, suggesting that PCR does not replace traditional culturing. PCR, however, accurately distinguishes fungal from bacterial pathogens [99]. In patients with suspected *Acanthamoeba* keratitis, PCR and *in-vivo* confocal microscopy (IVCM, see Section 7.5) are preferred over conventional cultures since the latter has a low sensitivity and requires special media and extended incubation periods [101]. Goh et al. compared traditional cultures, PCR, and IVCM in the early diagnosis of *Acanthamoeba* keratitis. All methods exhibited a specificity and positive predictive value of 100%. However, the diagnostic sensitivities were 100% for IVCM, 71.4% for PCR, and 33.3% for traditional cultures. Since IVCM is an expensive device and requires an experienced operator, PCR is considered as a valuable adjunct to cultures when *Acanthamoeba* is suspected [101].

7.4.2 Next-generation sequencing (NGS)

NGS encompasses an evolving group of high-throughput sequencing technologies which allow massive sequencing of nucleic acid. The Sanger (1970s), a precursor to NGS, is a first-generation sequencing platform with high accuracy when dealing with one bacterium. In fact, the Human Genome Project (2003) was completed with the automatization of this technique. Isolated bacterial sequencing required multiple reactions with the Sanger platform, and thus, it was complex and time consuming [102]. Second-generation platforms (Illumina HiSeq 2500), although able to generate high sequence throughput data in a single reaction, they only sequenced part of the 16S gene [94, 103, 104]. Current third-generation platforms use nanopore sequencing technology directly from clinical samples to diagnose bacterial keratitis in real time and with higher accuracy [98].

Metagenomic NGS (mNGS) is an emerging approach that analyzes microbial, and host's genetic material (DNA and RNA) in samples from patients [105]. mNGS may detect all potential pathogens (bacteria, fungi, parasites, and viruses) in a clinical or environmental sample and simultaneously interrogate host responses by performing billions of reads in a single run [105, 106]. Unfortunately, the untar-geted nature of this approach most likely results in host-derived reads [102].

Obtaining a rapid, real-time diagnosis of the causative microbe in bacterial keratitis will allow the ophthalmologist to initiate prompt and adequate antibiotic therapy; thus, improving the visual outcome and reducing antibiotic resistance [107]. However, test validation, reproducibility, high costs, among others, are significant drawbacks for the routine use of NGS and mNGS in clinical settings. Nevertheless, they must be considered in refractory difficult-to-identify cases of infection.

7.5 In vivo confocal microscopy (IVCM)

IVCM is a non-invasive imaging technique that allows dissection of the corneal architecture at a cellular level, providing real-time images equivalent to those obtained from ex-vivo histopathological techniques (tissue biopsy) [108]. It is currently used to evaluate corneal nerves in healthy eyes and those affected by ectatic corneal diseases, neurotrophic keratopathy, corneal dystrophies, ocular surface inflammation, contact lens wear, and infectious keratitis [108–110].

The role of IVCM in CLAIK relies on the identification of fungal hyphae and *Acanthamoeba* cysts; bacteria are too small to be visualized by IVCM [111]. Chidambaram et al. evaluated the IVCM cellular features in patients with bacterial, fungal, and *Acanthamoeba* keratitis [112]. A honeycomb-like distribution of anterior inflammatory cells in the corneal stroma was distinctive of fungal keratitis. *Aspergillus* and *Fusarium* ulcers were also associated with stromal dendritiform cells and interconnected cell processes with a stellate appearance, respectively. Bacterial keratitis was significantly associated with anterior stromal bullae and basal dendritiform cells. Normal keratocyte-like morphology was found in most eyes with both bacterial and fungal keratitis. Distinguishing features of *Acanthamoeba* included double-walled cysts, bright spots, and clusters after topical steroid use. While the keratocyte morphology was altered in 82% of bacterial (82%) and 77% of fungal keratitis, it was only abnormal in 39% of *Acanthamoeba* cases [112].

Although IVCM may be used in culture-negative cases or when the clinical diagnosis is unclear, this technique requires an experienced examiner. The rearmost since cellular features exhibited in microbial keratitis may be easily confused with nerve fibers, activated stromal keratocytes, and Langerhans cells [111]. Moreover, its small field of view precludes fair dismissal of *Acanthamoeba* cysts [113].

8. Differential diagnosis

8.1 Microorganism profile

According to the clinical features of the infectious/inflammatory process seen in CLAIK, specific differences, although not compelling, help identify the infectious agent involved in the process. For example, Gram-negative bacteria are usually associated with a significant anterior chamber reaction and larger ulcers compared to Gram-positive ones. Also, *Pseudomonas aeruginosa* tends to produce larger stromal inflammatory infiltrates [2, 40]. A study analyzing the causative microorganism involved in CLAIK found moderate positive prediction for *Acanthamoeba* annular

Figure 6.
 A. Sterile peripheral inflammatory infiltrate in the right eye due to corneal hypoxia and a tight lens fitting of a 26-year-old female wearing hydrogel-silicone, one-month schedule disposable contact lenses complaining of red-eye, foreign body sensation, and tearing from the past three days. B. Fluorescein staining shows a slight epithelial defect at the infiltrated site and superficial punctate keratitis.

stromal infiltrate at 89% (95% CI = 52–100) and *Pseudomonas* larger ulcer at 65% (95% CI = 43–84) [114]. On the other hand, pseudo-dendrites, epitheliopathy, and stromal infiltrate found in *Acanthamoeba* keratitis may confuse herpetic keratitis [115]. Serrated (feathery) ulcer margins with raised and dry texture infiltrate and satellite lesions are common features of fungal keratitis [116].

8.2 Infectious versus inflammatory keratitis

One of the first dilemmas confronted by professionals taking care of patients wearing contact lenses is to know if the corneal lesion is infectious or inflammatory (**Figure 6A** and **B**). The difficulty arises because the ocular immune response to foreign stimuli, including microbes and their products, foreign bodies, trauma, allergic and toxic reactions, is non-specific inflammation, which may be indistinguishable from infection in that respect [78, 117, 118]. A study asking ophthalmologists to identify sterile from culture-proven CLAIK found good predictability (76%, 95% CI = 67–84) with 79 cases classified correctly [114].

Some key clinical features help to differentiate between sterile from infectious keratitis. In sterile inflammation, the absence of eyelid edema, no conjunctival discharge, peripheral location of the lesion, and minimal or no anterior chamber reaction contrast with significant eyelid edema, abundant mucopurulent discharge, central/paracentral lesions, and severe reaction and hypopyon formation in infectious keratitis [78].

9. Management

First and foremost, efforts should be focused on the prevention of CLAIK. Wearers should be educated on the proper use of contact lenses. They should be counseled to avoid overnight wear and exposure to water and be educated on appropriate hygiene practices when handling contact lenses and timely contact lens replacement [35].

To make the right management decisions, recognizing the risk factors for CLAIK, its different clinical infectious patterns, and getting the causal microorganism identification/isolation are critical to obtaining an optimal therapeutic response, avoiding sight-threatening severe complications.

9.1 Bacterial keratitis

An early diagnosis and appropriate treatment of infectious keratitis are essential. Broad-spectrum topical antibiotics are the first-line therapy for bacterial keratitis and should be initiated immediately after cultures are obtained, while waiting for the results. Antibiotics should be indicated, taking into consideration the local epidemiological data, frequency of specific pathogens, and antibiotic sensitivities (**Table 5**) [82, 119]. Severe keratitis should be treated with an initial loading dose every 5 to 15 minutes for the first hour, followed by hourly instillation for 24 to 48 hours; a topical fortified antibiotic or fluoroquinolone may be used [119].

In a recent meta-analysis, no difference in effectiveness, defined as complete corneal re-epithelialization, was observed between the use of commercially available fourth-generation topical fluoroquinolones and aminoglycoside-cephalosporin fortified combinations; there was no difference in time to resolution either. However, symptoms of ocular discomfort and toxic conjunctivitis were more frequent when using fortified aminoglycoside-cephalosporin combinations (see Appendix 1) [119].

Treatment should be tapered according to response to a minimum of four times a day, avoiding toxicity from prolonged and unnecessary use of antibiotics [112]. If no clinical stabilization or improvement is observed after the first 48 hours of treatment, the therapeutic regimen should be modified; culture results and antibiotic sensitivity should guide the clinician under these conditions. Good therapeutic response features include decreased pain, conjunctival discharge, eyelid edema, reduced corneal stromal edema, a decreased anterior chamber response, and signs of re-epithelialization. Patients with severe keratitis should be followed daily until clinical improvement is observed. Cycloplegic agents may be indicated in cases of severe keratitis with significant anterior chamber reaction to prevent the formation of iridyneschia and reduce the pain [63].

The use of topical corticosteroids is controversial but may have a role in treating certain bacterial keratitis to reduce corneal scarring. According to a subgroup analysis of the Steroids for Corneal Ulcers Trial (SCUT) in non-*Nocardia* bacterial keratitis, topical corticosteroids within two to three days of topical antibiotic therapy resulted in a one-line improvement in visual acuity compared to placebo [120]. However, topical corticosteroid use in *Nocardia* ulcers was associated with larger scars at 12 months, and therefore, it is not recommended for these cases [121]. Other well-designed randomized clinical trials are necessary to confirm these findings [122].

9.2 Fungal keratitis

Fungal keratitis is often more aggressive than bacterial keratitis. However, there is no consensus on standard treatment, and randomized clinical trials on this subject are scarce [122]. Most antifungal medications available for ocular infections have significant limitations, including low bioavailability and limited ocular penetration in deep-seated lesions (**Table 6**) [123–125]. Furthermore, antifungal susceptibility testing has limited availability and is rarely used in ordinary contact lens and cornea clinics [126]. The Mycotic Ulcer Treatment Trial I (MUTT I) showed that topical natamycin is superior to topical voriconazole treating fungal keratitis in general, particularly in those caused by *Fusarium* [127]. According to the MUTT II results, there is no difference in perforation rate or need for therapeutic penetrating keratoplasty in fungal ulcers treated with oral voriconazole combined with topical antifungal agents compared to oral placebo and equal antifungal topical therapy. However, systemic adverse events were more frequent in the oral voriconazole group

Drug	Topical concentration	Subconjunctival dose	Activity
Cephalosporins: Inhibit bacterial cell wall formation by disrupting the synthesis of peptidoglycans. Less susceptibility to β-lactamases compared with penicillins.			
Cefazolin ¹	50 mg/mL	100 mg in 0.5 mL	Gram-positive cocci
Ceftriaxone	50 mg/mL	100 mg in 0.5 mL	Gram-negative cocci ²
Ceftazidime	50 mg/mL	100 mg in 0.5 mL	Gram-negative cocci / rods
Fluoroquinolones ¹ : Inhibit bacterial DNA gyrase and topoisomerase IV, enzymes required for bacterial DNA synthesis.			
Ciprofloxacin	3–6 mg/mL	Not available	Gram-negative cocci / rods
Ofloxacin	3–6 mg/mL	Not available	Gram-negative cocci / rods
Levofloxacin	5–15 mg/mL	Not available	+ gram-positive cocci
Moxifloxacin	5–6 mg/mL	Not available	+ gram-positive cocci and NTM
Gatifloxacin	5–6 mg/mL	Not available	
Besifloxacin	5–6 mg/mL	Not available	
Aminoglycosides: Bind to ribosomal subunits, resulting in defective mRNA translation and inhibition of protein biosynthesis.			
Gentamicin ¹	9–14 mg/mL	20 mg in 0.5 mL	Gram-negative rods
Tobramycin ¹	9–14 mg/mL	20 mg in 0.5 mL	Gram-negative rods
Amikacin	20–40 mg/mL	20 mg in 0.5 mL	NTM / <i>Nocardia</i>
Penicillins: Inhibit bacterial cell wall formation by disrupting the peptidoglycan synthesis.			
Penicillin G	100,000 U/mL	1,000,000 U/mL	Nonpenicillinase producing gram-positive organisms
Methicillin	50 mg/mL	200 mg/mL	Penicillinase-producing gram-positive organisms
Piperacillin	7 mg/mL	200 mg/mL	Gram-positives and some gram-negatives, including <i>Pseudomonas</i>
Glycopeptides: Inhibit cell wall formation of gram-positive bacteria			
Vancomycin ³	15–50 mg/mL	25 mg in 0.5 mL	Gram-positive cocci
Macrolides: Inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit.			
Erythromycin ⁴	5 mg/gram	Not available	Gram-positive bacteria
Clarithromycin	10 mg/mL	20 mg in 0.5 mL	NTM
Bacterial folic acid inhibitors: Folic acid, used in DNA synthesis is required by bacteria for growth and replication.			
Sulfacetamide ⁵	100 mg/mL	20 mg in 0.5 mL	<i>Nocardia</i>
TMP-SMX ⁶	16 mg/mL 80 mg/mL	20 mg in 0.5 mL	<i>Nocardia</i>

Adapted and modified from Mannis MJ and Holland EJ (Eds.). (2017). *Cornea*. Elsevier.
NTM, non-tuberculous mycobacteria; TMP-SMX, trimethoprim-sulfamethoxazole.¹Also used when no organism or multiple types or organisms are identified.
²Systemic therapy is required for suspected gonococcal infection.
³Potent activity against methicillin-resistant *Staphylococcus aureus*; used for resistant *Enterococcus* species and penicillin allergy. Must not be used as single therapy against bacterial keratitis due to poor gram-negative activity.
⁴Mostly used in ointment presentation for the management of blepharitis, rarely used in keratitis due to poor corneal penetration.
⁵Active against gram-negative and -positive bacteria; however, used because bacteria become highly resistant during therapy.
⁶Rarely used in bacterial keratitis due to poor corneal penetration when intact epithelium.

Table 5.
Topical and subconjunctival antibiotics and their indication for microbial keratitis.

Drug	Topical concentration	Coverage
Polyenes: bind to ergosterol in the fungal cell wall; disruption of cell wall Dose: initial dose of one drop every 30 minutes with tapering to every 3 to 6 hours		
Amphotericin B	0.05%–0.50%	First-line therapy for <i>Candida</i> ; good activity against <i>Aspergillus</i> and <i>Fusarium</i> .
Natamycin	2.5%–5%	<i>Aspergillus</i> , <i>Fusarium</i> ; moderate for <i>Candida</i>
Azoles: inhibit the synthesis of ergosterol through the cytochrome P-450-dependent enzyme Dose: undetermined		
Clotrimazole	1%	<i>Candida</i> , <i>Aspergillus</i>
Econazole	0.02%–2%	<i>Fusarium</i> , <i>Aspergillus</i> , <i>Candida</i>
Voriconazole	1%–2%	<i>Candida</i> , <i>Aspergillus</i>
Itraconazole	1%	<i>Candida</i> , <i>Aspergillus</i>
Fluconazole	0.5%–1%	<i>Candida</i> and other yeasts
Ketoconazole	1%–2%	<i>Candida</i> and <i>Aspergillus</i>
Echinocandins: block beta-glucan synthesis Dose: undetermined		
Caspofungin	0.5%	<i>Candida</i> , <i>Aspergillus</i>
Micafungin	0.1%	<i>Candida</i> , <i>Aspergillus</i>
Allylamines: block ergosterol biosynthesis by inhibition of squalene epoxidase Dose: undetermined		
Terbinafine	0.25%	<i>Aspergillus</i> , <i>Fusarium</i> and <i>Candida</i>
<i>Adapted and modified from Mannis MJ and Holland EJ (Eds.). (2017). Cornea. Elsevier.</i>		

Table 6.
Topical antifungals formulations for the treatment of mycotic keratitis.

[128]. According to a metanalysis of the available randomized clinical trials, there is still limited evidence to support using any particular drug or combination of drugs to treat fungal keratitis [129]. In general, topical treatment may include natamycin 5%, amphotericin-B 0.15% to 0.5 %, or voriconazole 1% or 2% [122].

9.3 Acanthamoeba keratitis

There is no consensus on the standard treatment for *Acanthamoeba* keratitis. Trophozoites are sensitive to a variety of antibiotics, antifungals, antiseptics, and antineoplastic agents. In contrast, cysts are highly resistant to a number of these drugs [113]. Effective topical treatment for *Acanthamoeba* cysts may include diamidines and biguanides such as propamidine-isethionate 0.1%, hexamidine-diisethionate 0.1%, dibromopropamidine 0.1%, polyhexamethylene-biguanide 0.02%, or chlorhexidine 0.02% [130]. A combination therapy of a biguanide and a diamidine is often used initially on an hourly schedule for the first 48 hours; treatment is then tapered according to the clinical response and potential epithelial toxicity and may be continued for several months. The objective is to eradicate *Acanthamoeba* trophozoites and cysts, with the resolution of the corneal inflammatory response [113].

9.4 Topical corticosteroids in infectious keratitis

The use of topical corticosteroids in infectious keratitis remains controversial [131]. Some authors advocate their use suggesting corticosteroids minimize corneal

inflammation, opacification, and neovascularization. Others oppose their use, claiming that they might exacerbate microbial replication, delay epithelial healing, accelerate stromal melting, and increase the risk of perforation [132]. Several authors have demonstrated in non-controlled studies that prior corticosteroid use in bacterial keratitis significantly increases the risk of antibiotic failure and corneal ulceration [132, 133]. A Cochrane review of three small randomized trials found no benefit in healing times or visual acuity outcomes with adjuvant corticosteroid treatment [134]. The Steroids for Corneal Ulcers Trial (SCUT), the largest randomized controlled trial to date, showed no overall benefit of steroid use in visual acuity, scar size, or perforation rate at 3-months follow-up [121]. Of note, steroids (prednisolone sodium phosphate 1%) or placebo were started after 48 hours of topical 0.5% moxifloxacin. The SCUT also demonstrated that adjuvant corticosteroids, compared to placebo, resulted in one-line improvement in visual acuity in non-*Nocardia* ulcers and more extensive scars in *Nocardia* ulcers at one year [121]. In a recent report by the American Academy of Ophthalmology, authors suggest using topical corticosteroids after 48 hours of antibiotic therapy in culture-positive non-*Nocardia* bacterial keratitis [122].

Similar results were described by Wouters et al. in eyes with *Acanthamoeba* keratitis [135]. Topical corticosteroid use was associated with a delay in diagnosis (23 vs. 62 days, $p < 0.001$), increased disease severity, worst visual outcomes ($\leq 20/80$, $p = 0.03$), and the need for an urgent corneal transplant [135].

In a recent murine model of *Candida albicans*, topical 0.1% dexamethasone exacerbated fungal keratitis by increasing the aggressivity of the pathogen, reducing the neutrophil infiltration, and inhibiting the formation of neutrophil extracellular traps [136].

9.5 Corneal collagen crosslinking (CXL)

Corneal CXL is a therapeutic modality consisting of photoactivation of a chromophore, riboflavin (vitamin-B₂), by ultraviolet (UVA) light at a wavelength of 370 nm. This technique is mainly used for stabilizing the corneal curvature and vision in patients with keratoconus and ectatic disorders [137, 138]. Studies suggest that guanine oxidation of nucleic acids and reactive oxygen species generation by activated riboflavin results in nucleic acid destruction with subsequent microbial proliferation. In 2013, the term photoactivated chromophore for infectious keratitis-corneal collagen crosslinking (PACK-CXL) emerged [137].

Price et al. performed the first prospective study assessing the efficacy of CXL in infectious keratitis [139]. PACK-CXL was deemed more effective for bacterial keratitis involving the superficial layers of the corneal stroma [139]. Another prospective clinical trial randomized 40 eyes to receive either PACK-CXL in addition to antimicrobial therapy or antimicrobial therapy alone [140]. Although PACK-CXL did not shorten the corneal healing time compared to the control group, it did result in an absent incidence of corneal perforation or recurrence of infection (0% vs. 21%) [140]. A recent meta-analysis performed by Ting et al., including four randomized-control trials, demonstrates that adjuvant PACK-CXL results in shorter mean healing times and quicker resolution of infiltrates when comparing with antimicrobial treatment alone. Despite the latter, high-quality randomized controlled trials are required to establish PACK-CXL's efficacy in infectious keratitis fully [141].

9.6 Rose bengal photodynamic antimicrobial therapy (RB-PDAT)

RB-PDAT is an emerging therapeutic modality for the management of infectious keratitis [142]. It was first introduced by Amescua et al. in 2017 for the management

of a patient with multidrug-resistant *Fusarium keratoplasticum* keratitis [143]. In this therapeutic modality, rose bengal, a routinely used dye in ophthalmology, is excited with a green light at a wavelength of 500–550 nm to generate reactive oxygen species [144]. Rose bengal is a type II photosensitizer that, when activated, induces cellular apoptosis by converting triplet oxygen to singlet oxygen [142]. A pilot study performed by Naranjo et al. including *Acanthamoeba* keratitis (10 cases), *Fusarium spp.* (4 cases), *Pseudomonas aeruginosa* (2 cases), and *Curvularia spp.* (1 case), evaluated the clinical outcomes of RB-PDAT. One patient had no microbiological diagnosis [144]. Most individuals (14/18, 79%) were contact-lens wearers. Successful therapy, defined as avoiding therapeutic keratoplasty, was achieved in 72% of the cases. Although adequately powered randomized controlled trials are required to ascertain the efficacy of RB-PDAT, preliminary results are promising.

9.7 Future drug-delivery systems

Despite the high efficacy and broad spectrum of the antimicrobials used in infectious keratitis, their insolubility in water, low precorneal residence time on the ocular surface, inadequate control of drug release and penetration, nasopharyngeal drainage, and toxicity hinders their performance [145]. To overcome such limitations, recent developments on drug-delivery systems are emerging.

Chhonker et al. developed amphotericin-B-loaded lecithin/chitosan nanoparticles with enhanced mucoadhesive properties for the prolonged ocular application [145]. The nanoparticles sized 161.9 to 230.5 nm improve drug bioavailability by approximately 2.04 fold and precorneal residence time by 3.36 fold in rabbit eyes [145]. Guo et al. developed self-assembled micelles of poly(ethylene glycol)-block-poly(glycidyl methacrylate) (PEG-b-PGMA) to deliver natamycin [146]. The sustained drug release from micelles allows reducing the frequency of natamycin application from 8 to only 3 times per day in rabbits with fungal keratitis. The use of contact lenses as drug carriers or sustained-release deposits has also been evaluated to improve antimicrobial efficacy. Huang et al. developed a hybrid hydrogel-based contact lens, loaded with voriconazole, comprised of quaternized chitosan, graphene oxide, and silver nanoparticles [147].

Another strategy employs carbon dots, which are small, highly fluorescent non-toxic element nanoparticles that measure less than 10 nm and are considered to replace metal-based quantum dots [148]. Zhao et al. demonstrated that nitrogen-doped carbon quantum dots sized 2–5 nm can destroy the cell structure of *Staphylococcus aureus* and methicillin-resistant *Staphylococcus aureus* (MRSA) [149].

There is a paucity of studies evaluating the efficacy of drug-delivery mechanisms to manage infectious keratitis in humans. Such mechanisms may enhance drug penetration, better compliance, and reduced toxicity, thus improving patient outcomes.

9.8 Surgical procedures

Surgical management must be considered to maintain the globe integrity in patients with unresponsive keratitis associated with severe stromal melt with impending perforation risk. Zhong et al. demonstrated that full-thickness conjunctival flap covering surgery with amniotic membrane transplantation might represent a viable option to save the eyeball for eyes with severe fungal keratitis without corneal perforation [150]. In their series, most eyes (15/17, 88%) achieved complete conjunctival re-epithelization. Seven of them achieved a mean best-corrected visual acuity of ~20/100, remaining disease-free at least one month after

sclerokeratoplasty [150]. However, melting of the conjunctival flap, with subsequent endophthalmitis requiring evisceration, occurred in two eyes.

Therapeutic keratoplasty (TKP) should be reserved for patients who are not candidates for other therapies, and if possible, after quiescent infection [151]. In *Acanthamoeba* keratitis, TKP is recommended in cases of corneal perforation unresponsive to repeat gluing, severe corneal abscess, or significant cataract [113]. Because of the risk of rejection with large grafts in *Acanthamoeba* keratitis, corneal grafts must be kept to the minimum size required [113]. In cases of fungal keratitis, Selver et al. demonstrated that smaller grafts (≤ 8 mm) were associated with lower rejection rates, but higher recurrence rates possibly related to incomplete removal of infected tissue [151, 152].

10. Conclusions

Despite significant technological development in contact lens materials resulting in remarkable improvement in safety and comfort, microbial keratitis continues to be a severe sight-threatening complication in contact lens wearers. Overnight extended contact lens wear and deficient lenses and case hygiene continue to be the primary risk factors for CLAIK worldwide; hence improvement in contact lens hygiene, education, and handling is necessary to reduce this potential complication.

The clinician must be able to promptly recognize the condition and identify the causative microorganism through corneal scraping, smear, and culture in case of severe keratitis, and treat the disease according to the suspected etiological agent; Empirical treatment must be initiated in every case and modified according to the clinical response and microbiology laboratory results.

Appendix

Fortified topical antibiotic formulations and mode of preparation

---

Tobramycin 14 mg/mL or gentamicin 14 mg/mL

1. Withdraw 2 mL of either drug from an injectable vial (40 mg/mL).
2. Add 2 mL to an ophthalmic solution (5 mg) of either drug to give a 14 mg/mL solution.
3. Refrigerate and shake prior to instillation.

Cefazolin 50 mg/mL or ceftazidime 50 mg/mL

1. Add 9.3 mL of lubricant eyedrops to a vial of either drug, 1 g (powder for injection).
2. Dissolve. Take 5 mL and add it to 5 mL of lubricant eyedrops.
3. Refrigerate and shake prior to instillation.

Amikacin 10–40 mg/mL

1. Dilute intravenous formulation (80 mg/2 mL ampules) with lubricant eyedrops or 0.9% sodium chloride for injection USP to the desired concentration.
2. Refrigerate and shake prior to instillation.

Vancomycin 15 mg/mL, 25 mg/mL, or 50 mg/mL

1. Add either 33 mL, 20 mL, or 10 mL of 0.9% sodium chloride for injection USP, or artificial tears, to a vial of 500 mg of vancomycin to produce a solution of 15, 25, or 50 mg/mL, respectively.
  2. Refrigerate and shake prior to instillation.
-

Linezolid 2 mg/mL (for methicillin-resistant <i>Staphylococcus aureus</i>)
1. May be used directly from parenteral linezolid intravenous infusion available as 200 mg/100 mL.
Colistin 0.19% (for multiple drug-resistant <i>Pseudomonas aeruginosa</i>)
1. Add 1 million UI / 75 mg of parenteral colistimethate sodium powder to 10 ml of distilled water to obtain 7.5 mg/mL.
2. Withdraw 1 mL of the above solution and add to 3 mL of distilled water to obtain a 0.19% concentration
Trimethoprim (16 mg/mL) - sulfamethoxazole (80 mg/mL)
1. Commercial intravenous preparation may be used as topical solution without preparation.
Imipenem – cilastin (1%)
1. Add 10 mL of sterile water to parenteral imipenem (500 mg) – cilastin (500 mg) to create a 50 mg/mL solution.
2. Withdraw 1 mL of the above solution and add 4 mL of sterile water to make topical 1% imipenem to obtain 1 mg/mL
3. Storage in amber-colored bottles

Data retrieved from [153].

Author details

Jimena Alamillo-Velazquez, Raul E. Ruiz-Lozano, Julio C. Hernandez-Camarena and Alejandro Rodriguez-Garcia*
Tecnologico de Monterrey, School of Medicine and Health Sciences, Institute of Ophthalmology and Visual Sciences, Monterrey, Mexico

*Address all correspondence to: immuneye@gmail.com

IntechOpen

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

- [1] Forister JFY, Forister EF, Yeung KK, et al. Prevalence of contact lens-related complications: UCLA contact lens study. *Eye Contact Lens*. 2009;35(4):176-180. doi:10.1097/ICL.0b013e3181a7bda1
- [2] Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. *Br J Ophthalmol*. 2003;87(7):834-838. doi:10.1136/bjo.87.7.834
- [3] Edwards K, Keay L, Naduvilath T, Snibson G, Taylor H, Stapleton F. Characteristics of and risk factors for contact lens-related microbial keratitis in a tertiary referral hospital. *Eye Lond Engl*. 2009;23(1):153-160. doi:10.1038/sj.eye.6702953
- [4] Fong C-F, Tseng C-H, Hu F-R, Wang I-J, Chen W-L, Hou Y-C. Clinical characteristics of microbial keratitis in a university hospital in Taiwan. *Am J Ophthalmol*. 2004;137(2):329-336. doi:10.1016/j.ajo.2003.09.001
- [5] Erie JC, Nevitt MP, Hodge DO, Ballard DJ. Incidence of ulcerative keratitis in a defined population from 1950 through 1988. *Arch Ophthalmol Chic Ill 1960*. 1993;111(12):1665-1671. doi:10.1001/archophth.1993.01090120087027
- [6] Upadhyay M, Karmacharya P, Koirala S, et al. The Bhaktapur eye study: ocular trauma and antibiotic prophylaxis for the prevention of corneal ulceration in Nepal. *Br J Ophthalmol*. 2001;85(4):388-392. doi:10.1136/bjo.85.4.388
- [7] Hsiao C-H. Pediatric Microbial Keratitis in Taiwanese Children: A Review of Hospital Cases. *Arch Ophthalmol*. 2007;125(5):603. doi:10.1001/archophth.125.5.603
- [8] Khor W-B, Prajna VN, Garg P, et al. The Asia Cornea Society Infectious Keratitis Study: A Prospective Multicenter Study of Infectious Keratitis in Asia. *Am J Ophthalmol*. 2018;195:161-170. doi:10.1016/j.ajo.2018.07.040
- [9] Li W, Sun X, Wang Z, Zhang Y. A survey of contact lens-related complications in a tertiary hospital in China. *Contact Lens Anterior Eye J Br Contact Lens Assoc*. 2018;41(2):201-204. doi:10.1016/j.clae.2017.10.007
- [10] Liesegang TJ. Contact lens-related microbial keratitis: Part I: Epidemiology. *Cornea*. 1997;16(2):125-131.
- [11] Stapleton F. Contact lens-related microbial keratitis: what can epidemiologic studies tell us? *Eye Contact Lens*. 2003;29(1 Suppl):S85-89; discussion S115-118, S192-194. doi:10.1097/00140068-200301001-00024
- [12] Stapleton F, Keay L, Edwards K, et al. The incidence of contact lens-related microbial keratitis in Australia. *Ophthalmology*. 2008;115(10):1655-1662. doi:10.1016/j.ophtha.2008.04.002
- [13] Stapleton F, Keay L, Edwards K, Holden B. The epidemiology of microbial keratitis with silicone hydrogel contact lenses. *Eye Contact Lens*. 2013;39(1):79-85. doi:10.1097/ICL.0b013e3182713919
- [14] Watt K, Swarbrick HA. Microbial keratitis in overnight orthokeratology: review of the first 50 cases. *Eye Contact Lens*. 2005;31(5):201-208. doi:10.1097/01.icl.0000179705.23313.7e
- [15] Steinemann TL, Pinninti U, Szczotka LB, Eiferman RA, Price FW. Ocular complications associated with the use of cosmetic contact lenses from unlicensed vendors. *Eye Contact Lens*. 2003;29(4):196-200. doi:10.1097/00140068-200310000-00002

- [16] Sauer A, Bourcier T, French Study Group for Contact Lenses Related Microbial Keratitis. Microbial keratitis as a foreseeable complication of cosmetic contact lenses: a prospective study. *Acta Ophthalmol (Copenh)*. 2011;89(5):e439-442. doi:10.1111/j.1755-3768.2011.02120.x
- [17] Spornovasilis N, Maraki S, Kokorakis E, et al. Antimicrobial susceptibility of isolated pathogens from patients with contact lens-related bacterial keratitis in Crete, Greece: A ten-year analysis. *Contact Lens Anterior Eye J Br Contact Lens Assoc*. Published online August 8, 2020;101355. doi:10.1016/j.clae.2020.07.006
- [18] Stapleton F, Keay LJ, Sanfilippo PG, Katiyar S, Edwards KP, Naduvilath T. Relationship between climate, disease severity, and causative organism for contact lens-associated microbial keratitis in Australia. *Am J Ophthalmol*. 2007;144(5):690-698. doi:10.1016/j.ajo.2007.06.037
- [19] Rattanatham T, Heng WJ, Rapuano CJ, Laibson PR, Cohen EJ. Trends in contact lens-related corneal ulcers. *Cornea*. 2001;20(3):290-294. doi:10.1097/00003226-200104000-00010
- [20] Yildiz EH, Airiani S, Hammersmith KM, et al. Trends in contact lens-related corneal ulcers at a tertiary referral center. *Cornea*. 2012;31(10):1097-1102. doi:10.1097/ICO.0b013e318221cee0
- [21] Mah-Sadorra JH, Yavuz SGA, Najjar DM, Laibson PR, Rapuano CJ, Cohen EJ. Trends in contact lens-related corneal ulcers. *Cornea*. 2005;24(1):51-58. doi:10.1097/01.ico.0000138839.29823.57
- [22] Stapleton F, Naduvilath T, Keay L, et al. Risk factors and causative organisms in microbial keratitis in daily disposable contact lens wear. *PloS One*. 2017;12(8):e0181343. doi:10.1371/journal.pone.0181343
- [23] Bottone EJ, Cho KW. Mycobacterium chelonae keratitis: elucidation of diagnosis through evaluation of smears of fluid from patient's contact lens care system. *Cornea*. 2005;24(3):356-358. doi:10.1097/01.ico.0000138858.95516.c5
- [24] Allan BD, Dart JK. Strategies for the management of microbial keratitis. *Br J Ophthalmol*. 1995;79(8):777-786.
- [25] Kaye R, Kaye A, Sueke H, et al. Recurrent bacterial keratitis. *Invest Ophthalmol Vis Sci*. 2013;54(6):4136-4139. doi:10.1167/iovs.13-12130
- [26] Patel A, Hammersmith K. Contact lens-related microbial keratitis: recent outbreaks. *Curr Opin Ophthalmol*. 2008;19(4):302-306. doi:10.1097/ICU.0b013e3283045e74
- [27] Khor W-B, Aung T, Saw S-M, et al. An Outbreak of Fusarium Keratitis Associated With Contact Lens Wear in Singapore. *JAMA*. 2006;295(24):2867. doi:10.1001/jama.295.24.2867
- [28] Alfonso EC, Cantu-Dibildox J, Munir WM, et al. Insurgence of Fusarium keratitis associated with contact lens wear. *Arch Ophthalmol Chic Ill 1960*. 2006;124(7):941-947. doi:10.1001/archophth.124.7.ecs60039
- [29] Bernal MD, Acharya NR, Lietman TM, Strauss EC, McLeod SD, Hwang DG. Outbreak of Fusarium keratitis in soft contact lens wearers in San Francisco. *Arch Ophthalmol Chic Ill 1960*. 2006;124(7):1051-1053. doi:10.1001/archophth.124.7.ecr60006
- [30] Chang DC, Grant GB, O'Donnell K, et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. *JAMA*. 2006;296(8):953-963. doi:10.1001/jama.296.8.953

- [31] Zhang S, Ahearn DG, Noble-Wang JA, et al. Growth and survival of *Fusarium solani*-F. oxysporum complex on stressed multipurpose contact lens care solution films on plastic surfaces in situ and in vitro. *Cornea*. 2006;25(10):1210-1216. doi:10.1097/ICO.0b013e31802dd3a4
- [32] Joslin CE, Tu EY, Shoff ME, et al. The association of contact lens solution use and *Acanthamoeba* keratitis. *Am J Ophthalmol*. 2007;144(2):169-180. doi:10.1016/j.ajo.2007.05.029
- [33] Karaca I, Barut Selver O, Palamar M, Egrilmez S, Aydemir S, Yagci A. Contact Lens-Associated Microbial Keratitis in a Tertiary Eye Care Center in Turkey. *Eye Contact Lens*. 2020;46(2):110-115. doi:10.1097/ICL.0000000000000617
- [34] Ahn M, Yoon K-C, Ryu S-K, Cho N-C, You I-C. Clinical aspects and prognosis of mixed microbial (bacterial and fungal) keratitis. *Cornea*. 2011;30(4):409-413. doi:10.1097/ico.0b013e3181f23704
- [35] Keay L, Stapleton F. Development and evaluation of evidence-based guidelines on contact lens-related microbial keratitis. *Contact Lens Anterior Eye J Br Contact Lens Assoc*. 2008;31(1):3-12. doi:10.1016/j.clae.2007.10.003
- [36] Dart JKG, Radford CF, Minassian D, Verma S, Stapleton F. Risk factors for microbial keratitis with contemporary contact lenses: a case-control study. *Ophthalmology*. 2008;115(10):1647-1654, 1654.e1-3. doi:10.1016/j.ophtha.2008.05.003
- [37] Schein OD, Glynn RJ, Poggio EC, Seddon JM, Kenyon KR. The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group. *N Engl J Med*. 1989;321(12):773-778. doi:10.1056/NEJM198909213211201
- [38] Radford CF, Lehmann OJ, Dart JK. *Acanthamoeba* keratitis: multicentre survey in England 1992-6. National *Acanthamoeba* Keratitis Study Group. *Br J Ophthalmol*. 1998;82(12):1387-1392. doi:10.1136/bjo.82.12.1387
- [39] Phillips SP. Defining and measuring gender: A social determinant of health whose time has come. *Int J Equity Health*. 2005;4:11. doi:10.1186/1475-9276-4-11
- [40] Lim CHL, Carnt NA, Farook M, et al. Risk factors for contact lens-related microbial keratitis in Singapore. *Eye Lond Engl*. 2016;30(3):447-455. doi:10.1038/eye.2015.250
- [41] Carnt N, Hoffman JJ, Verma S, et al. *Acanthamoeba* keratitis: confirmation of the UK outbreak and a prospective case-control study identifying contributing risk factors. *Br J Ophthalmol*. 2018;102(12):1621-1628. doi:10.1136/bjophthalmol-2018-312544
- [42] Keay L, Edwards K, Naduvilath T, et al. Microbial Keratitis: Predisposing Factors and Morbidity. *Ophthalmology*. 2006;113(1):109-116. doi:10.1016/j.ophtha.2005.08.013
- [43] Carnt NA, Willcox MDP, Hau S, et al. Association of Single Nucleotide Polymorphisms of Interleukins-1 β , -6, and -12B with Contact Lens Keratitis Susceptibility and Severity. *Ophthalmology*. 2012;119(7):1320-1327. doi:10.1016/j.ophtha.2012.01.031
- [44] Sankaridurg PR, Sharma S, Willcox M, et al. Bacterial colonization of disposable soft contact lenses is greater during corneal infiltrative events than during asymptomatic extended lens wear. *J Clin Microbiol*. 2000;38(12):4420-4424. doi:10.1128/JCM.38.12.4420-4424.2000
- [45] Soumpasis I, Knapp L, Pitt T. A proof-of-concept model for the identification of the key events in the

- p>infection process with specific reference to
- Pseudomonas aeruginosa*
- in corneal infections.
- Infect Ecol Epidemiol*
- . 2015;5:28750. doi:10.3402/iee.v5.28750
- [46] Stapleton F, Tan J. Impact of Contact Lens Material, Design, and Fitting on Discomfort. *Eye Contact Lens*. 2017;43(1):32-39. doi:10.1097/ICL.0000000000000318
- [47] Zaidi T, Mowrey-McKee M, Pier GB. Hypoxia increases corneal cell expression of CFTR leading to increased *Pseudomonas aeruginosa* binding, internalization, and initiation of inflammation. *Invest Ophthalmol Vis Sci*. 2004;45(11):4066-4074. doi:10.1167/iovs.04-0627
- [48] Imayasu M, Petroll WM, Jester JV, Patel SK, Ohashi J, Cavanagh HD. The relation between contact lens oxygen transmissibility and binding of *Pseudomonas aeruginosa* to the cornea after overnight wear. *Ophthalmology*. 1994;101(2):371-388. doi:10.1016/s0161-6420(94)31326-1
- [49] Ren DH, Yamamoto K, Ladage PM, et al. Adaptive effects of 30-night wear of hyper-O(2) transmissible contact lenses on bacterial binding and corneal epithelium: a 1-year clinical trial. *Ophthalmology*. 2002;109(1):27-39; discussion 39-40. doi:10.1016/s0161-6420(01)00867-3
- [50] Cavanagh HD, Ladage PM, Li SL, et al. Effects of daily and overnight wear of a novel hyper oxygen-transmissible soft contact lens on bacterial binding and corneal epithelium: a 13-month clinical trial. *Ophthalmology*. 2002;109(11):1957-1969. doi:10.1016/s0161-6420(02)01278-2
- [51] Wu YT, Zhu LS, Tam KPC, Evans DJ, Fleiszig SMJ. *Pseudomonas aeruginosa* Survival at Posterior Contact Lens Surfaces after Daily Wear. *Optom Vis Sci Off Publ Am Acad Optom*. 2015;92(6):659-664. doi:10.1097/OPX.0000000000000597
- [52] McNamara NA, Polse KA, Brand RJ, Graham AD, Chan JS, McKenney CD. Tear mixing under a soft contact lens: effects of lens diameter. *Am J Ophthalmol*. 1999;127(6):659-665. doi:10.1016/s0002-9394(99)00051-3
- [53] Paugh JR, Stapleton F, Keay L, Ho A. Tear Exchange under Hydrogel Contact Lenses: Methodological Considerations. *Invest Ophthalmol Vis Sci*. 2001;42(12):2813-2820.
- [54] Fleiszig SMJ, Evans DJ. Pathogenesis of contact lens-associated microbial keratitis. *Optom Vis Sci Off Publ Am Acad Optom*. 2010;87(4):225-232. doi:10.1097/OPX.0b013e3181d408ee
- [55] Stapleton F, Dart JK, Seal DV, Matheson M. Epidemiology of *Pseudomonas aeruginosa* keratitis in contact lens wearers. *Epidemiol Infect*. 1995;114(3):395-402.
- [56] McLaughlin-Borlace L, Stapleton F, Matheson M, Dart JK. Bacterial biofilm on contact lenses and lens storage cases in wearers with microbial keratitis. *J Appl Microbiol*. 1998;84(5):827-838. doi:10.1046/j.1365-2672.1998.00418.x
- [57] Anwar H, Dasgupta MK, Costerton JW. Testing the susceptibility of bacteria in biofilms to antibacterial agents. *Antimicrob Agents Chemother*. 1990;34(11):2043-2046.
- [58] Szczotka-Flynn LB, Imamura Y, Chandra J, et al. Increased resistance of contact lens-related bacterial biofilms to antimicrobial activity of soft contact lens care solutions. *Cornea*. 2009;28(8):918-926. doi:10.1097/ICO.0b013e3181a81835
- [59] Vijay AK, Sankaridurg P, Zhu H, Willcox MDP. Guinea pig models of acute keratitis responses. *Cornea*. 2009;28(10):1153-1159. doi:10.1097/ICO.0b013e3181a87a0b
- [60] Willcox MDP, Naduvilath TJ, Vaddavalli PK, Holden BA, Ozkan J,

Zhu H. Corneal erosions, bacterial contamination of contact lenses, and microbial keratitis. *Eye Contact Lens*. 2010;36(6):340-345. doi:10.1097/ICL.0b013e3181f57b05

[61] Carnt NA, Evans VE, Naduvilath TJ, et al. Contact lens-related adverse events and the silicone hydrogel lenses and daily wear care system used. *Arch Ophthalmol Chic Ill 1960*. 2009;127(12):1616-1623. doi:10.1001/archophthalmol.2009.313

[62] Dumbleton K. Noninflammatory silicone hydrogel contact lens complications. *Eye Contact Lens*. 2003;29(1 Suppl):S186-189; discussion S190-191, S192-194. doi:10.1097/S00140068-200301001-00051

[63] Poggio EC, Glynn RJ, Schein OD, et al. The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. *N Engl J Med*. 1989;321(12):779-783. doi:10.1056/NEJM198909213211202

[64] Cheung N, Nagra P, Hammersmith K. Emerging trends in contact lens-related infections. *Curr Opin Ophthalmol*. 2016;27(4):327-332. doi:10.1097/ICU.0000000000000280

[65] Goodlaw E. Risk of infection from sleeping with contact lenses on: causes of risk. *Optom Vis Sci Off Publ Am Acad Optom*. 1996;73(3):156-158. doi:10.1097/00006324-199603000-00005

[66] Zimmerman AB, Nixon AD, Rueff EM. Contact lens associated microbial keratitis: practical considerations for the optometrist. *Clin Optom*. 2016;8:1-12. doi:10.2147/OPTO.S66424

[67] Das S, Sheorey H, Taylor HR, Vajpayee RB. Association between cultures of contact lens and corneal scraping in contact lens related

microbial keratitis. *Arch Ophthalmol Chic Ill 1960*. 2007;125(9):1182-1185. doi:10.1001/archophth.125.9.1182

[68] Stapleton F, Carnt N. Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis. *Eye Lond Engl*. 2012;26(2):185-193. doi:10.1038/eye.2011.288

[69] Alipour F, Khaheshi S, Soleimanzadeh M, Heidarzadeh S, Heydarzadeh S. Contact Lens-related Complications: A Review. *J Ophthalmic Vis Res*. 2017;12(2):193-204. doi:10.4103/jovr.jovr_159_16

[70] Fonn D, Jones L. Hand hygiene is linked to microbial keratitis and corneal inflammatory events. *Contact Lens Anterior Eye J Br Contact Lens Assoc*. 2019;42(2):132-135. doi:10.1016/j.clae.2018.10.022

[71] Stellwagen A, MacGregor C, Kung R, Konstantopoulos A, Hossain P. Personal hygiene risk factors for contact lens-related microbial keratitis. *BMJ Open Ophthalmol*. 2020;5(1). doi:10.1136/bmjophth-2020-000476

[72] Keay L, Stapleton F, Schein O. Epidemiology of contact lens-related inflammation and microbial keratitis: a 20-year perspective. *Eye Contact Lens*. 2007;33(6 Pt 2):346-353, discussion 362-363. doi:10.1097/ICL.0b013e318157c49d

[73] Ladage PM, Yamamoto K, Ren DH, et al. Proliferation rate of rabbit corneal epithelium during overnight rigid contact lens wear. *Invest Ophthalmol Vis Sci*. 2001;42(12):2804-2812.

[74] Ladage PM, Jester JV, Petroll WM, Bergmanson JPG, Cavanagh HD. Vertical Movement of Epithelial Basal Cells toward the Corneal Surface during Use of Extended-Wear Contact Lenses. *Invest Ophthalmol Vis Sci*.

2003;44(3):1056-1063. doi:10.1167/iov.02-0725

[75] Willcox MDP, Holden BA. Contact Lens Related Corneal Infections. *Biosci Rep.* 2001;21(4):445-461. doi:10.1023/A:1017991709846

[76] Holden BA, Sankaridurg PR, Sweeney DF, Stretton S, Naduvilath TJ, Rao GN. Microbial keratitis in prospective studies of extended wear with disposable hydrogel contact lenses. *Cornea.* 2005;24(2):156-161. doi:10.1097/01.icc.0000138844.90668.91

[77] Keay L, Edwards K, Stapleton F. Signs, symptoms, and comorbidities in contact lens-related microbial keratitis. *Optom Vis Sci Off Publ Am Acad Optom.* 2009;86(7):803-809. doi:10.1097/OPX.0b013e3181ae1b69

[78] Aasuri MK, Venkata N, Kumar VM. Differential diagnosis of microbial keratitis and contact lens-induced peripheral ulcer. *Eye Contact Lens.* 2003;29(1 Suppl):S60-62; discussion S83-84, S192-194. doi:10.1097/00140068-200301001-00017

[79] Dalmon C, Porco TC, Lietman TM, et al. The Clinical Differentiation of Bacterial and Fungal Keratitis: A Photographic Survey. *Invest Ophthalmol Vis Sci.* 2012;53(4):1787-1791. doi:10.1167/iov.11-8478

[80] Eltis M. Contact-lens-related microbial keratitis: case report and review. *J Optom.* 2011;4(4):122-127. doi:10.1016/S1888-4296(11)70053-X

[81] Labetoulle M, Frau E, Offret H, Nordmann P, Naas T. Non-preserved 1% lidocaine solution has less antibacterial properties than currently available anaesthetic eye-drops. *Curr Eye Res.* 2002;25(2):91-97. doi:10.1076/ceyr.25.2.91.10159

[82] Lin A, Rhee MK, Akpek EK, et al. Bacterial Keratitis Preferred Practice Pattern®. *Ophthalmology.* 2019;126(1):P1-P55. doi:10.1016/j.optha.2018.10.018

[83] Sharma S, Kunimoto DY, Gopinathan U, Athmanathan S, Garg P, Rao GN. Evaluation of corneal scraping smear examination methods in the diagnosis of bacterial and fungal keratitis: a survey of eight years of laboratory experience. *Cornea.* 2002;21(7):643-647. doi:10.1097/00003226-200210000-00002

[84] Sharma S. Diagnosis of fungal keratitis: current options. *Expert Opin Med Diagn.* 2012;6(5):449-455. doi:10.1517/17530059.2012.679656

[85] Hong, Augustine. Bacterial Keratitis. In: *Cornea: Fundamentals, Diagnosis and Management.* Fifth Edition. Elsevier; 2022:802-824.

[86] Mela EK, Giannelou IP, Koliopoulos JX, Gartaganis SP, John KX, Sotirios GP. Ulcerative keratitis in contact lens wearers. *Eye Contact Lens.* 2003;29(4):207-209. doi:10.1097/01.icl.0000078102.30635.A7

[87] Musa F, Tailor R, Gao A, Hutley E, Rauz S, Scott R a. H. Contact lens-related microbial keratitis in deployed British military personnel. *Br J Ophthalmol.* 2010;94(8):988-993. doi:10.1136/bjo.2009.161430

[88] Lam DSC, Houang E, Fan DSP, et al. Incidence and risk factors for microbial keratitis in Hong Kong: comparison with Europe and North America. *Eye Lond Engl.* 2002;16(5):608-618. doi:10.1038/sj.eye.6700151

[89] Martins EN, Farah ME, Alvarenga LS, Yu MCZ, Höflin-Lima AL. Infectious keratitis: correlation between corneal and contact lens cultures. *CLAO J Off Publ Contact*

Lens Assoc Ophthalmol Inc.
2002;28(3):146-148.

2007;449(7164):804-810. doi:10.1038/nature06244

[90] Alexandrakis G, Haimovici R, Miller D, Alfonso EC. Corneal biopsy in the management of progressive microbial keratitis. *Am J Ophthalmol.* 2000;129(5):571-576. doi:10.1016/s0002-9394(99)00449-3

[98] Low L, Fuentes-Utrilla P, Hodson J, et al. Evaluation of full-length nanopore 16S sequencing for detection of pathogens in microbial keratitis. *PeerJ.* 2021;9:e10778. doi:10.7717/peerj.10778

[91] Lee P, Green WR. Corneal Biopsy: Indications, Techniques, and a Report of a Series of 87 Cases. *Ophthalmology.* 1990;97(6):718-721. doi:10.1016/S0161-6420(90)32517-4

[99] Kim E, Chidambaram JD, Srinivasan M, et al. Prospective comparison of microbial culture and polymerase chain reaction in the diagnosis of corneal ulcer. *Am J Ophthalmol.* 2008;146(5):714-723, 723.e1. doi:10.1016/j.ajo.2008.06.009

[92] Newton C, Moore MB, Kaufman HE. Corneal biopsy in chronic keratitis. *Arch Ophthalmol Chic Ill 1960.* 1987;105(4):577-578. doi:10.1001/archophth.1987.01060040147053

[100] Borst A, Box ATA, Fluit AC. False-positive results and contamination in nucleic acid amplification assays: suggestions for a prevent and destroy strategy. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol.* 2004;23(4):289-299. doi:10.1007/s10096-004-1100-1

[93] Epstein SS. The phenomenon of microbial uncultivability. *Curr Opin Microbiol.* 2013;16(5):636-642. doi:10.1016/j.mib.2013.08.003

[101] Goh JWY, Harrison R, Hau S, Alexander CL, Tole DM, Avadhanam VS. Comparison of In Vivo Confocal Microscopy, PCR and Culture of Corneal Scrapes in the Diagnosis of Acanthamoeba Keratitis. *Cornea.* 2018;37(4):480-485. doi:10.1097/ICO.0000000000001497

[94] Winand R, Bogaerts B, Hoffman S, et al. Targeting the 16S rRNA Gene for Bacterial Identification in Complex Mixed Samples: Comparative Evaluation of Second (Illumina) and Third (Oxford Nanopore Technologies) Generation Sequencing Technologies. *Int J Mol Sci.* 2019;21(1). doi:10.3390/ijms21010298

[102] Ung L, Bispo PJM, Doan T, et al. Clinical metagenomics for infectious corneal ulcers: Rags to riches? *Ocul Surf.* 2020;18(1):1-12. doi:10.1016/j.jtos.2019.10.007

[95] Fleiszig SMJ, Kroken AR, Nieto V, et al. Contact lens-related corneal infection: Intrinsic resistance and its compromise. *Prog Retin Eye Res.* 2020;76:100804. doi:10.1016/j.preteyeres.2019.100804

[103] Holm JB, Humphrys MS, Robinson CK, et al. Ultrahigh-Throughput Multiplexing and Sequencing of >500-Base-Pair Amplicon Regions on the Illumina HiSeq 2500 Platform. *mSystems.* 2019;4(1). doi:10.1128/mSystems.00029-19

[96] Gaudio PA, Gopinathan U, Sangwan V, Hughes TE. Polymerase chain reaction based detection of fungi in infected corneas. *Br J Ophthalmol.* 2002;86(7):755-760. doi:10.1136/bjo.86.7.755

[97] Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. *Nature.*

[104] Johnson JS, Spakowicz DJ, Hong B-Y, et al. Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis. *Nat Commun.*

2019;10(1):5029. doi:10.1038/s41467-019-13036-1

[105] Chiu CY, Miller SA. Clinical metagenomics. *Nat Rev Genet.* 2019;20(6):341-355. doi:10.1038/s41576-019-0113-7

[106] Shigeyasu C, Yamada M, Aoki K, et al. Metagenomic analysis for detecting *Fusarium solani* in a case of fungal keratitis. *J Infect Chemother Off J Jpn Soc Chemother.* 2018;24(8):664-668. doi:10.1016/j.jiac.2017.12.019

[107] Kuo M-T, Chen J-L, Hsu S-L, Chen A, You H-L. An Omics Approach to Diagnosing or Investigating Fungal Keratitis. *Int J Mol Sci.* 2019;20(15). doi:10.3390/ijms20153631

[108] Cruzat A, Qazi Y, Hamrah P. In Vivo Confocal Microscopy of Corneal Nerves in Health and Disease. *Ocul Surf.* 2017;15(1):15-47. doi:10.1016/j.jtos.2016.09.004

[109] Ruiz-Lozano RE, Hernandez-Camarena JC, Loya-Garcia D, Merayo-Llodes J, Rodriguez-Garcia A. The molecular basis of neurotrophic keratopathy: Diagnostic and therapeutic implications. A review. *Ocul Surf.* 2021;19:224-240. doi:10.1016/j.jtos.2020.09.007

[110] Saliman NH, Morgan PB, MacDonald AS, Maldonado-Codina C. Subclinical Inflammation of the Ocular Surface in Soft Contact Lens Wear. *Cornea.* 2020;39(2):146-154. doi:10.1097/ICO.0000000000002192

[111] Carnt N, Samarawickrama C, White A, Stapleton F. The diagnosis and management of contact lens-related microbial keratitis. *Clin Exp Optom.* 2017;100(5):482-493. doi:10.1111/cxo.12581

[112] Chidambaram JD, Prajna NV, Palepu S, et al. In Vivo Confocal

Microscopy Cellular Features of Host and Organism in Bacterial, Fungal, and Acanthamoeba Keratitis. *Am J Ophthalmol.* 2018;190:24-33. doi:10.1016/j.ajo.2018.03.010

[113] Maycock NJR, Jayaswal R. Update on Acanthamoeba Keratitis: Diagnosis, Treatment, and Outcomes. *Cornea.* 2016;35(5):713-720. doi:10.1097/ICO.0000000000000804

[114] Dahlgren MA, Lingappan A, Wilhelmus KR. The clinical diagnosis of microbial keratitis. *Am J Ophthalmol.* 2007;143(6):940-944. doi:10.1016/j.ajo.2007.02.030

[115] Carnt N, Robaei D, Watson SL, Minassian DC, Dart JKG. The Impact of Topical Corticosteroids Used in Conjunction with Antiamoebic Therapy on the Outcome of Acanthamoeba Keratitis. *Ophthalmology.* 2016;123(5):984-990. doi:10.1016/j.opthta.2016.01.020

[116] Thomas PA, Leck AK, Myatt M. Characteristic clinical features as an aid to the diagnosis of suppurative keratitis caused by filamentous fungi. *Br J Ophthalmol.* 2005;89(12):1554-1558. doi:10.1136/bjo.2005.076315

[117] Sweeney DF, Jalbert I, Covey M, et al. Clinical characterization of corneal infiltrative events observed with soft contact lens wear. *Cornea.* 2003;22(5):435-442. doi:10.1097/00003226-200307000-00009

[118] Carnt N, Stapleton F. Silicone hydrogel lens-solution interaction and inflammation. *Eye Contact Lens.* 2013;39(1):37-41. doi:10.1097/ICL.0b013e31827d4ba1

[119] McDonald EM, Ram FSF, Patel DV, McGhee CNJ. Topical antibiotics for the management of bacterial keratitis: an evidence-based review of high quality randomised controlled trials. *Br J*

Ophthalmol. 2014;98(11):1470-1477.
doi:10.1136/bjophthalmol-2013-304660

[120] Ray KJ, Srinivasan M, Mascarenhas J, et al. Early addition of topical corticosteroids in the treatment of bacterial keratitis. *JAMA Ophthalmol.* 2014;132(6):737-741. doi:10.1001/jamaophthalmol.2014.292

[121] Srinivasan M, Mascarenhas J, Rajaraman R, et al. The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial. *Am J Ophthalmol.* 2014;157(2):327-333.e3. doi:10.1016/j.ajo.2013.09.025

[122] Austin A, Lietman T, Rose-Nussbaumer J. Update on the Management of Infectious Keratitis. *Ophthalmology.* 2017;124(11):1678-1689. doi:10.1016/j.ophtha.2017.05.012

[123] Qiu S, Zhao G-Q, Lin J, et al. Natamycin in the treatment of fungal keratitis: a systematic review and Meta-analysis. *Int J Ophthalmol.* 2015;8(3):597-602. doi:10.3980/j.issn.2222-3959.2015.03.29

[124] Ansari Z, Miller D, Galor A. Current Thoughts in Fungal Keratitis: Diagnosis and Treatment. *Curr Fungal Infect Rep.* 2013;7(3):209-218. doi:10.1007/s12281-013-0150-110.1007/s12281-013-0150-1

[125] Chang H-YP, Chodosh J. Diagnostic and therapeutic considerations in fungal keratitis. *Int Ophthalmol Clin.* 2011;51(4):33-42. doi:10.1097/IIO.0b013e31822d64dc

[126] Shapiro BL, Lalitha P, Loh AR, et al. Susceptibility testing and clinical outcome in fungal keratitis. *Br J Ophthalmol.* 2010;94(3):384-385. doi:10.1136/bjo.2009.158675

[127] Prajna NV, Krishnan T, Mascarenhas J, et al. The Mycotic Ulcer Treatment Trial. *JAMA Ophthalmol.* 2013;131(4):422-429.

[128] Prajna NV, Krishnan T, Rajaraman R, et al. Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): A Randomized Clinical Trial. *JAMA Ophthalmol.* 2016;134(12):1365-1372. doi:10.1001/jamaophthalmol.2016.4096

[129] FlorCruz NV, Peczon IV, Evans JR. Medical interventions for fungal keratitis. *Cochrane Database Syst Rev.* 2012;(2):CD004241. doi:10.1002/14651858.CD004241.pub3

[130] Szentmáry N, Daas L, Shi L, et al. Acanthamoeba keratitis - Clinical signs, differential diagnosis and treatment. *J Curr Ophthalmol.* 2019;31(1):16-23. doi:10.1016/j.joco.2018.09.008

[131] Palioura S, Henry CR, Amescua G, Alfonso EC. Role of steroids in the treatment of bacterial keratitis. *Clin Ophthalmol Auckl NZ.* 2016;10:179-186. doi:10.2147/OPTH.S80411

[132] Wilhelmus KR. Indecision about corticosteroids for bacterial keratitis: an evidence-based update. *Ophthalmology.* 2002;109(5):835-842; quiz 843. doi:10.1016/s0161-6420(02)00963-6

[133] Wang JC, Su D, Lim L. Contact lens microbial keratitis and prior topical steroid use: a disaster in the making? *Ann Acad Med Singapore.* 2004;33(4):484-488.

[134] Herretes S, Wang X, Reyes JMG. Topical corticosteroids as adjunctive therapy for bacterial keratitis. *Cochrane Database Syst Rev.* 2014;(10):CD005430. doi:10.1002/14651858.CD005430.pub3

[135] Wouters KA, Verhoekx JS, van Rooij J, Wubbels R, van Goor AT. Topical corticosteroids in Acanthamoeba keratitis: Friend or foe? *Eur J Ophthalmol.* Published online November 13, 2020:1120672120973606. doi:10.1177/1120672120973606

- [136] Fan F, Huang X, Yuan K, et al. Glucocorticoids May Exacerbate Fungal Keratitis by Increasing Fungal Aggressivity and Inhibiting the Formation of Neutrophil Extracellular Traps. *Curr Eye Res.* 2020;45(2):124-133. doi:10.1080/02713683.2019.1657464
- [137] Bonzano C, Di Zazzo A, Barabino S, Coco G, Traverso CE. Collagen Cross-Linking in the Management of Microbial Keratitis. *Ocul Immunol Inflamm.* 2019;27(3):507-512. doi:10.1080/09273948.2017.1414856
- [138] Hernandez-Camarena JC, Graue-Hernandez EO, Loya-García D, Ruiz-Lozano RE, Valdez-García JE. Correlation between corneal stromal demarcation line depth and topographic outcomes after two pulsed-light-accelerated crosslinking protocols. *Clin Ophthalmol Auckl NZ.* 2019;13:1665-1673. doi:10.2147/OPTH.S206103
- [139] Price MO, Tenkman LR, Schrier A, Fairchild KM, Trokel SL, Price FW. Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. *J Refract Surg Thorofare NJ* 1995. 2012;28(10):706-713. doi:10.3928/1081597X-20120921-06
- [140] Said DG, Elalfy MS, Gatziofufas Z, et al. Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. *Ophthalmology.* 2014;121(7):1377-1382. doi:10.1016/j.ophtha.2014.01.011
- [141] Ting DSJ, Henein C, Said DG, Dua HS. Photoactivated chromophore for infectious keratitis - Corneal cross-linking (PACK-CXL): A systematic review and meta-analysis. *Ocul Surf.* 2019;17(4):624-634. doi:10.1016/j.jtos.2019.08.006
- [142] Naranjo A, Pelaez D, Arrieta E, et al. Cellular and molecular assessment of rose bengal photodynamic antimicrobial therapy on keratocytes, corneal endothelium and limbal stem cell niche. *Exp Eye Res.* 2019;188:107808. doi:10.1016/j.exer.2019.107808
- [143] Amescua G, Arboleda A, Nikpoor N, et al. Rose Bengal Photodynamic Antimicrobial Therapy: A Novel Treatment for Resistant Fusarium Keratitis. *Cornea.* 2017;36(9):1141-1144. doi:10.1097/ICO.0000000000001265
- [144] Naranjo A, Arboleda A, Martinez JD, et al. Rose Bengal Photodynamic Antimicrobial Therapy for Patients With Progressive Infectious Keratitis: A Pilot Clinical Study. *Am J Ophthalmol.* 2019;208:387-396. doi:10.1016/j.ajo.2019.08.027
- [145] Chhonker YS, Prasad YD, Chandasana H, et al. Amphotericin-B entrapped lecithin/chitosan nanoparticles for prolonged ocular application. *Int J Biol Macromol.* 2015;72:1451-1458. doi:10.1016/j.ijbiomac.2014.10.014
- [146] Guo Y, Karimi F, Fu Q, G Qiao G, Zhang H. Reduced administration frequency for the treatment of fungal keratitis: a sustained natamycin release from a micellar solution. *Expert Opin Drug Deliv.* 2020;17(3):407-421. doi:10.1080/17425247.2020.1719995
- [147] Huang J-F, Zhong J, Chen G-P, et al. A Hydrogel-Based Hybrid Theranostic Contact Lens for Fungal Keratitis. *ACS Nano.* 2016;10(7):6464-6473. doi:10.1021/acsnano.6b00601
- [148] Ghosal K, Ghosh A. Carbon dots: The next generation platform for biomedical applications. *Mater Sci Eng C Mater Biol Appl.* 2019;96:887-903. doi:10.1016/j.msec.2018.11.060
- [149] Zhao C, Wang X, Wu L, et al. Nitrogen-doped carbon quantum dots as an antimicrobial agent against Staphylococcus for the treatment of infected wounds. *Colloids Surf B*

Biointerfaces. 2019;179:17-27.
doi:10.1016/j.colsurfb.2019.03.042

[150] Zhong J, Wang B, Li S, et al.
Full-thickness conjunctival flap
covering surgery combined with
amniotic membrane transplantation for
severe fungal keratitis. *Exp Ther Med*.
2018;15(3):2711-2718. doi:10.3892/
etm.2018.5765

[151] Sha X-Y, Shi Q, Liu L, Zhong J-X.
Update on the management of fungal
keratitis. *Int Ophthalmol*. Published
online April 30, 2021. doi:10.1007/
s10792-021-01873-3

[152] Barut Selver O, Egrilmez S,
Palamar M, Arici M, Hilmioglu Polat S,
Yagci A. Therapeutic Corneal
Transplant for Fungal Keratitis
Refractory to Medical Therapy. *Exp Clin
Transplant Off J Middle East Soc Organ
Transplant*. 2015;13(4):355-359.
doi:10.6002/ect.2014.0108

[153] Nixon, H. K. (2018). Preparation of
fortified antimicrobial eye drops. *Kerala
Journal of Ophthalmology*, 30(2), 152.